NASDAQ:NTRA - Natera Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.62 +0.25 (+2.20 %)
(As of 05/27/2018 09:30 AM ET)
Previous Close$11.62
Today's Range$11.37 - $11.71
52-Week Range$7.78 - $14.76
Volume166,453 shs
Average Volume172,250 shs
Market Capitalization$633.44 million
P/E Ratio-4.84
Dividend YieldN/A
Beta2.07

About Natera (NASDAQ:NTRA)

Natera logoNatera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090

Debt

Debt-to-Equity Ratio-18.90
Current Ratio1.80
Quick Ratio1.68

Price-To-Earnings

Trailing P/E Ratio-4.84
Forward P/E Ratio-5.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$210.94 million
Price / Sales3.00
Cash FlowN/A
Price / CashN/A
Book Value($0.07) per share
Price / Book-166.00

Profitability

EPS (Most Recent Fiscal Year)($2.40)
Net Income$-136,310,000.00
Net Margins-58.84%
Return on Equity-752.93%
Return on Assets-66.23%

Miscellaneous

Employees893
Outstanding Shares54,510,000

Natera (NASDAQ:NTRA) Frequently Asked Questions

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

How were Natera's earnings last quarter?

Natera Inc (NASDAQ:NTRA) released its quarterly earnings results on Tuesday, May, 8th. The medical research company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.01. The medical research company earned $62.34 million during the quarter, compared to analyst estimates of $54.86 million. Natera had a negative net margin of 58.84% and a negative return on equity of 752.93%. The firm's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.70) earnings per share. View Natera's Earnings History.

What price target have analysts set for NTRA?

5 brokerages have issued twelve-month target prices for Natera's stock. Their predictions range from $12.00 to $16.00. On average, they anticipate Natera's stock price to reach $14.75 in the next twelve months. View Analyst Ratings for Natera.

Who are some of Natera's key competitors?

Who are Natera's key executives?

Natera's management team includes the folowing people:
  • Dr. Matthew Rabinowitz, Co-Founder, CEO, Pres & Chairman (Age 45)
  • Mr. Michael Brophy, Chief Financial Officer (Age 38)
  • Mr. Steve Chapman, Chief Operating Officer (Age 39)
  • Mr. Jonathan Sheena M.Eng., Co-Founder, Chief Technology Officer and Director (Age 45)
  • Mr. Daniel Rabinowitz L.L.M., LL.M., Corp. Sec. and Gen. Counsel

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Has Natera been receiving favorable news coverage?

Headlines about NTRA stock have trended somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Natera earned a media sentiment score of 0.12 on Accern's scale. They also gave news headlines about the medical research company an impact score of 46.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Natera's major shareholders?

Natera's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sofinnova Ventures Inc (5.69%), Kornitzer Capital Management Inc. KS (1.08%), Northern Trust Corp (0.69%), Asymmetry Capital Management L.P. (0.60%), Millennium Management LLC (0.58%) and Schwab Charles Investment Management Inc. (0.32%). Company insiders that own Natera stock include Claremont Creek Partners Fund, Herm Rosenman, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Roelof Botha and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.

Which major investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Principal Financial Group Inc. and Principal Financial Group Inc.. Company insiders that have sold Natera company stock in the last year include Claremont Creek Partners Fund, Jonathan Sheena, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera.

Which major investors are buying Natera stock?

NTRA stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Millennium Management LLC, Asymmetry Capital Management L.P., Kornitzer Capital Management Inc. KS, Schwab Charles Investment Management Inc., A.R.T. Advisors LLC, Trexquant Investment LP and Swiss National Bank. View Insider Buying and Selling for Natera.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $11.62.

How big of a company is Natera?

Natera has a market capitalization of $633.44 million and generates $210.94 million in revenue each year. The medical research company earns $-136,310,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Natera employs 893 workers across the globe.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090.


MarketBeat Community Rating for Natera (NTRA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  307
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Natera (NASDAQ:NTRA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Natera in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible upside of 26.94%. The high price target for NTRA is $16.00 and the low price target for NTRA is $12.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.75$14.75$14.3333$15.00
Price Target Upside: 26.94% upside67.61% upside45.52% upside60.60% upside

Natera (NASDAQ:NTRA) Consensus Price Target History

Price Target History for Natera (NASDAQ:NTRA)

Natera (NASDAQ:NTRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$15.00 ➝ $16.00LowView Rating Details
4/9/2018Craig HallumInitiated CoverageBuy$16.00HighView Rating Details
12/21/2017CowenReiterated RatingBuy$12.00LowView Rating Details
11/14/2017Canaccord GenuityReiterated RatingBuy$15.00N/AView Rating Details
10/24/2017Robert W. BairdReiterated RatingBuyN/AView Rating Details
11/10/2016BenchmarkBoost Price TargetBuy$16.00 ➝ $20.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Natera (NASDAQ:NTRA) Earnings History and Estimates Chart

Earnings by Quarter for Natera (NASDAQ:NTRA)

Natera (NASDAQ:NTRA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.55)($0.55)($0.55)
Q3 20181($0.48)($0.48)($0.48)
Q4 20181($0.40)($0.40)($0.40)
Q1 20191($0.36)($0.36)($0.36)
Q2 20191($0.31)($0.31)($0.31)
Q3 20191($0.20)($0.20)($0.20)

Natera (NASDAQ NTRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.60)($0.61)$54.86 million$62.34 millionViewN/AView Earnings Details
3/13/2018Q4 2017($0.46)($0.73)$56.83 million$53.80 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.47)($0.5070)$55.31 million$56.66 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.52)($0.52)$50.57 million$53.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.61)($0.70)$42.82 million$46.90 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.54)($0.72)$49.82 million$49.30 millionViewListenView Earnings Details
11/9/2016Q316($0.55)($0.50)$48.14 million$53.89 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($0.46)$50.64 million$52.00 millionViewListenView Earnings Details
5/10/2016Q116($0.46)($0.17)$48.17 million$61.90 millionViewListenView Earnings Details
3/8/2016Q415($0.64)($0.47)$45.26 million$52.90 millionViewListenView Earnings Details
11/12/2015Q315($0.46)($0.39)$43.08 million$44.90 millionViewListenView Earnings Details
8/12/2015Q2 2015($0.45)($2.98)$42.69 million$45.09 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Natera (NASDAQ:NTRA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Natera (NASDAQ NTRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.18%
Institutional Ownership Percentage: 72.28%
Insider Trading History for Natera (NASDAQ:NTRA)
Insider Trading History for Natera (NASDAQ:NTRA)

Natera (NASDAQ NTRA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Claremont Creek Partners FundMajor ShareholderSell25,027$11.59$290,062.93View SEC Filing  
5/14/2018Claremont Creek Partners FundMajor ShareholderSell37,540$11.48$430,959.20View SEC Filing  
3/26/2018Michael Burkes BrophyCFOSell1,449$9.74$14,113.264,468View SEC Filing  
3/26/2018Steven Leonard ChapmanCOOSell1,997$9.74$19,450.784,468View SEC Filing  
9/6/2017Jonathan SheenaInsiderSell120,000$12.54$1,504,800.00533,208View SEC Filing  
4/5/2017Herm RosenmanDirectorSell1,809$8.55$15,466.9542,950View SEC Filing  
1/4/2017Herm RosenmanCFOSell1,849$11.87$21,947.6333,409View SEC Filing  
12/22/2016Jonathan SheenaInsiderSell16,213$12.00$194,556.00645,972View SEC Filing  
12/20/2016Jonathan SheenaInsiderSell1,087$12.00$13,044.00630,846View SEC Filing  
12/13/2016Jonathan SheenaInsiderSell2,700$12.00$32,400.00632,459View SEC Filing  
12/6/2016Herm RosenmanCFOSell1,828$11.83$21,625.2430,237View SEC Filing  
12/5/2016Matthew RabinowitzCEOSell14,021$12.02$168,532.421,888,644View SEC Filing  
12/1/2016Matthew RabinowitzCEOSell56,072$12.01$673,424.721,942,572View SEC Filing  
11/28/2016Matthew RabinowitzCEOSell146,756$12.50$1,834,450.002,020,876View SEC Filing  
11/21/2016Jonathan SheenaInsiderSell32,505$12.00$390,060.00630,165View SEC Filing  
11/3/2016Herm RosenmanCFOSell1,852$7.98$14,778.96View SEC Filing  
10/6/2016Herm RosenmanCFOSell1,773$11.53$20,442.6922,051View SEC Filing  
10/5/2016Jonathan SheenaInsiderSell1,600$12.00$19,200.00617,151View SEC Filing  
9/6/2016Herm RosenmanCFOSell1,822$10.21$18,602.6218,873View SEC Filing  
8/2/2016Herm RosenmanCFOSell1,833$12.98$23,792.3415,706View SEC Filing  
7/6/2016Herm RosenmanCFOSell1,824$12.10$22,070.4012,530View SEC Filing  
7/1/2016Matthew RabinowitzCEOSell104,892$12.14$1,273,388.882,167,354View SEC Filing  
6/19/2016Jonathan SheenaCTOSell188,442$11.94$2,249,997.48598,420View SEC Filing  
6/19/2016Matthew RabinowitzCEOSell732,831$11.94$8,750,002.142,876,595View SEC Filing  
6/19/2016Roelof BothaDirectorBuy837,521$11.94$10,000,000.74View SEC Filing  
6/2/2016Herm RosenmanCFOSell1,806$12.04$21,744.249,336View SEC Filing  
2/1/2016Jonathan SheenaCTOSell10,000$8.03$80,300.00615,551View SEC Filing  
1/5/2016Matthew RabinowitzCEOSell54,683$10.37$567,062.712,762,777View SEC Filing  
1/4/2016Jonathan SheenaCTOSell25,000$10.06$251,500.00622,551View SEC Filing  
12/31/2015Matthew RabinowitzCEOSell111,513$10.83$1,207,685.792,817,460View SEC Filing  
12/29/2015Jonathan SheenaCTOSell50,000$10.44$522,000.00640,051View SEC Filing  
12/29/2015Matthew RabinowitzCEOSell83,804$10.62$889,998.482,928,973View SEC Filing  
7/8/2015James HealyDirectorBuy350,000$18.00$6,300,000.00View SEC Filing  
7/2/2015James HealyDirectorBuy400,000$22.81$9,124,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Natera (NASDAQ NTRA) News Headlines

Source:
DateHeadline
Naturally Splendid Engages Doctor as Qualified Person In Charge and Advisory Board MemberNaturally Splendid Engages Doctor as Qualified Person In Charge and Advisory Board Member
www.nasdaq.com - May 23 at 9:18 AM
OpGen (OPGN) versus Natera (NTRA) Financial ReviewOpGen (OPGN) versus Natera (NTRA) Financial Review
www.americanbankingnews.com - May 19 at 3:37 PM
Insider Selling: Natera Inc (NTRA) Major Shareholder Sells 25,027 Shares of StockInsider Selling: Natera Inc (NTRA) Major Shareholder Sells 25,027 Shares of Stock
www.americanbankingnews.com - May 17 at 8:15 PM
$60.32 Million in Sales Expected for Natera Inc (NTRA) This Quarter$60.32 Million in Sales Expected for Natera Inc (NTRA) This Quarter
www.americanbankingnews.com - May 16 at 3:46 AM
Claremont Creek Partners Fund Sells 37,540 Shares of Natera Inc (NTRA) StockClaremont Creek Partners Fund Sells 37,540 Shares of Natera Inc (NTRA) Stock
www.americanbankingnews.com - May 15 at 10:10 PM
Natera (NTRA) Lowered to Hold at ValuEngineNatera (NTRA) Lowered to Hold at ValuEngine
www.americanbankingnews.com - May 15 at 11:34 AM
 Analysts Expect Natera Inc (NTRA) to Post -$0.53 EPS Analysts Expect Natera Inc (NTRA) to Post -$0.53 EPS
www.americanbankingnews.com - May 14 at 9:35 AM
Q2 2018 EPS Estimates for Natera Inc Reduced by Piper Jaffray (NTRA)Q2 2018 EPS Estimates for Natera Inc Reduced by Piper Jaffray (NTRA)
www.americanbankingnews.com - May 11 at 8:35 AM
Natera Inc (NTRA) Receives Average Rating of "Buy" from AnalystsNatera Inc (NTRA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 10 at 4:37 PM
Edited Transcript of NTRA earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of NTRA earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:49 AM
Morgan Stanley Raises Natera (NTRA) Price Target to $16.00Morgan Stanley Raises Natera (NTRA) Price Target to $16.00
www.americanbankingnews.com - May 9 at 4:43 PM
Natera (NTRA) Posts Quarterly  Earnings Results, Misses Estimates By $0.01 EPSNatera (NTRA) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 9 at 1:43 PM
Natera: 1Q Earnings SnapshotNatera: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:39 AM
Contrasting Natera (NTRA) & Quest Diagnostics (DGX)Contrasting Natera (NTRA) & Quest Diagnostics (DGX)
www.americanbankingnews.com - May 3 at 9:43 PM
Natera (NTRA) Stock Rating Upgraded by ValuEngineNatera (NTRA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 11:36 PM
Natera (NTRA) to Release Earnings on MondayNatera (NTRA) to Release Earnings on Monday
www.americanbankingnews.com - May 2 at 8:32 PM
Natera Inc. Announces First Quarter 2018 Earnings Conference CallNatera Inc. Announces First Quarter 2018 Earnings Conference Call
www.prnewswire.com - May 1 at 6:12 PM
Head-To-Head Comparison: Fulgent Genetics (FLGT) versus Natera (NTRA)Head-To-Head Comparison: Fulgent Genetics (FLGT) versus Natera (NTRA)
www.americanbankingnews.com - May 1 at 3:12 PM
Natera Inc (NTRA) Expected to Post Quarterly Sales of $55.39 MillionNatera Inc (NTRA) Expected to Post Quarterly Sales of $55.39 Million
www.americanbankingnews.com - April 28 at 2:10 AM
Natera Inc (NTRA) Expected to Post Earnings of -$0.54 Per ShareNatera Inc (NTRA) Expected to Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 26 at 9:20 PM
Natera (NTRA) Upgraded by BidaskClub to "Hold"Natera (NTRA) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 21 at 7:24 AM
ValuEngine Downgrades Natera (NTRA) to Strong SellValuEngine Downgrades Natera (NTRA) to Strong Sell
www.americanbankingnews.com - April 16 at 7:35 PM
Natera (NTRA) Downgraded to Hold at BidaskClubNatera (NTRA) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - April 16 at 8:18 AM
Natera Inc (NTRA) Given Consensus Rating of "Hold" by BrokeragesNatera Inc (NTRA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 11:29 AM
Natera (NTRA) & Its Peers Financial ReviewNatera (NTRA) & Its Peers Financial Review
www.americanbankingnews.com - April 15 at 7:21 AM
Natera (NTRA) Downgraded by BidaskClubNatera (NTRA) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 5:18 PM
Natera (NTRA) vs. The Competition Head-To-Head ComparisonNatera (NTRA) vs. The Competition Head-To-Head Comparison
www.americanbankingnews.com - April 14 at 7:43 AM
Natera to Present Successful Results at AACR from Bladder and Colon Cancer StudiesNatera to Present Successful Results at AACR from Bladder and Colon Cancer Studies
finance.yahoo.com - April 13 at 4:21 PM
Natera (NTRA) Upgraded by Zacks Investment Research to "Buy"Natera (NTRA) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 11 at 5:35 PM
Natera (NTRA) Lifted to Sell at ValuEngineNatera (NTRA) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 11 at 3:58 PM
Natera (NTRA) Upgraded to "Hold" at ValuEngineNatera (NTRA) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 11 at 12:04 PM
Natera (NTRA) Rating Increased to Sell at BidaskClubNatera (NTRA) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM
Natera Inc (NTRA) Expected to Post Quarterly Sales of $55.51 MillionNatera Inc (NTRA) Expected to Post Quarterly Sales of $55.51 Million
www.americanbankingnews.com - April 11 at 1:44 AM
Financial Analysis: Natera (NTRA) & Its CompetitorsFinancial Analysis: Natera (NTRA) & Its Competitors
www.americanbankingnews.com - April 10 at 7:09 PM
Natera To Present New Data at ACMG Annual MeetingNatera To Present New Data at ACMG Annual Meeting
finance.yahoo.com - April 10 at 10:01 AM
Natera Inc (NTRA) Expected to Announce Earnings of -$0.54 Per ShareNatera Inc (NTRA) Expected to Announce Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 9 at 11:17 PM
Benzingas Top Upgrades, Downgrades For April 9, 2018Benzinga's Top Upgrades, Downgrades For April 9, 2018
www.benzinga.com - April 9 at 9:51 AM
Natera Appoints Paul R. Billings, MD, Ph.D., as Chief Medical OfficerNatera Appoints Paul R. Billings, MD, Ph.D., as Chief Medical Officer
www.prnewswire.com - April 9 at 9:51 AM
Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical OfficerNatera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer
finance.yahoo.com - April 9 at 9:51 AM
Natera (NTRA) Research Coverage Started at Craig HallumNatera (NTRA) Research Coverage Started at Craig Hallum
www.americanbankingnews.com - April 9 at 8:25 AM
Critical Survey: Natera (NTRA) & Its RivalsCritical Survey: Natera (NTRA) & Its Rivals
www.americanbankingnews.com - April 8 at 3:08 AM
Natera (NTRA) Downgraded by Zacks Investment Research to HoldNatera (NTRA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 4 at 11:26 PM
Head-To-Head Review: Natera (NTRA) and The CompetitionHead-To-Head Review: Natera (NTRA) and The Competition
www.americanbankingnews.com - April 4 at 3:06 AM
Critical Review: Natera (NTRA) & Its CompetitorsCritical Review: Natera (NTRA) & Its Competitors
www.americanbankingnews.com - April 1 at 1:16 PM
Contrasting Natera (NTRA) and Its CompetitorsContrasting Natera (NTRA) and Its Competitors
www.americanbankingnews.com - March 31 at 11:16 PM
Form 4 Natera, Inc. For: Mar 26 Filed by: Brophy Michael BurkesForm 4 Natera, Inc. For: Mar 26 Filed by: Brophy Michael Burkes
www.streetinsider.com - March 29 at 10:03 AM
Why Hemp Could Become the Next Biggest Cash Crop and How to Profit -- CFN MediaWhy Hemp Could Become the Next Biggest Cash Crop and How to Profit -- CFN Media
globenewswire.com - March 29 at 10:03 AM
Natera Inc (NTRA) CFO Michael Burkes Brophy Sells 1,449 SharesNatera Inc (NTRA) CFO Michael Burkes Brophy Sells 1,449 Shares
www.americanbankingnews.com - March 28 at 11:10 PM
Insider Selling: Natera Inc (NTRA) COO Sells 1,997 Shares of StockInsider Selling: Natera Inc (NTRA) COO Sells 1,997 Shares of Stock
www.americanbankingnews.com - March 28 at 11:10 PM
Natera (NTRA) Downgraded to Sell at Zacks Investment ResearchNatera (NTRA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 26 at 9:18 PM

SEC Filings

Natera (NASDAQ:NTRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Natera (NASDAQ:NTRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Natera (NASDAQ NTRA) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.